Sarepta Therapeutics (SRPT +1.7%) adjusted net loss widens to $14.6M from $5M a year earlier.
Net loss $19.1M vs a profit of $8M
Revenue drops to $3M from $11.2M last year, mainly due to the termination of a government contract in August 2012.
Cash, cash equivalents and restricted investments $164M as of June 30 vs $187.7M as of December 31.
From the end of Q2 and up until August 7, Sarepta raised $37.9M and issued 1M shares of stock under an "At-The-Market" (ATM) equity financing that was put in place in July.
Results of Phase IIB trial of Sarepta's eteplirsen drug for Duchenne muscular dystrophy get their first peer review with an article in the Annals of Neurology. The study is due to form the basis of an FDA NDA in H1 next year. (PR)